Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.

You may also be interested in...



Deals Of The Week: BioCryst/Presidio, Merck/AiCuris, Kite/National Cancer Institute

The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.

Medivation Battles UCLA Over Rights To Prostate Cancer Compound

UCLA researchers secretly developed a compound almost identical to Medivation’s MDV3100 (enzalutamide), a breach of contract suit claims. The company expects to launch MDV3100 later this year.

MedImmune’s Alzheimer’s Antibody Partnership With Axerion Showcases Virtual Neuroscience R&D Operation

The two companies will work together to optimize and develop preclinical antibodies targeted at blocking amyloid-beta oligomer binding to cellular prion protein.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel